Viking Therapeutics, Inc. (VKTX): Total Assets
$715.73M
As of 2025-12-31
$521.90M
As of 2026-06-30
+61.9%
3-year compound annual growth
+22.8%
5-year compound annual growth
+46.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $715.73M | -21.2% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $908.32M | +146.5% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $368.49M | +118.7% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $168.53M | -20.0% | 2024-02-07, Balance as of period end |
| 2021-12-31 | $210.66M | -17.9% | 2023-02-10, Balance as of period end |
| 2020-12-31 | $256.50M | -9.8% | 2022-02-09, Balance as of period end |
| 2019-12-31 | $284.26M | -6.0% | 2021-02-17, Balance as of period end |
| 2018-12-31 | $302.31M | n/m | 2020-02-26, Balance as of period end |
| 2017-12-31 | $22.12M | +52.2% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $14.54M | -5.9% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $15.44M | +407.3% | 2017-03-21, Balance as of period end |
| 2014-12-31 | $3.04M | n/a | 2016-03-08, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $715.73M | -21.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare VKTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗